Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma.
The prognosis of patients with renal cell carcinoma (RCC) is poor. A full understanding of the molecular genetics and signaling pathways involved in renal cancer development and in the metastatic process is of central importance for developing innovative and novel treatment options. In this study, BD Atlas Human Cancer 1.2 cDNA microarrays were used to identify genes involved in renal tumorigenesis. By analyzing gene expression patterns of four clear cell RCC (cRCC) cell lines and normal renal tissue, 25 genes were found differentially expressed. To determine the relevance of these genes, RNA in situ hybridization was performed on a tissue microarray generated from 61 snap-frozen primary renal cell carcinomas and 12 normal renal cortex biopsies. B-cell translocation gene 2 (BTG2), a negative cell cycle regulator, which was expressed in normal renal tissue but down-regulated in cRCC cell lines and primary cRCCs, was selected for additional experiments. Quantitative BTG2 mRNA expression analysis in 42 primary cRCCs and 18 normal renal cortex biopsies revealed up to 44-fold reduced expression in the tumor tissues. Decrease of BTG2 expression was not associated with tumor stage, grade, and survival. Cell culture experiments demonstrated that BTG2 expression was weakly inducible by the phorbolester 12-O-tetradecanoylphorbol-13-acetate in one of four cRCC cell lines. In contrast, increasing cell density led to elevated BTG2 mRNA expression in three of four cRCC cell lines. In both experiments, BTG2 mRNA levels did not reach values observed in normal renal tissue. These data suggest that down-regulation of BTG2 is an important step in renal cancer development.
Institute for Pathology, University of Basel, Basel, Switzerland.
Kirsten
K
Struckmann
Peter
P
Schraml
Ronald
R
Simon
Katja
K
Elmenhorst
Martina
M
Mirlacher
Juha
J
Kononen
Holger
H
Moch
D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism* / Q000473:pathology; D015152:Blotting, Northern; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000473:pathology; D002452:Cell Count; D002453:Cell Cycle; D045744:Cell Line, Tumor; D005786:Gene Expression Regulation / Q000187:drug effects; D016147:Genes, Tumor Suppressor; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics*; D017403:In Situ Hybridization; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D025521:Tumor Suppressor Proteins
D017874:Immediate-Early Proteins; D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins; C070114:BTG2 protein, human; D013755:Tetradecanoylphorbol Acetate